Compare MGY & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGY | CRSP |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.7B |
| IPO Year | 2017 | 2016 |
| Metric | MGY | CRSP |
|---|---|---|
| Price | $26.71 | $52.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 19 |
| Target Price | $26.23 | ★ $67.78 |
| AVG Volume (30 Days) | ★ 3.5M | 1.8M |
| Earning Date | 02-05-2026 | 02-12-2026 |
| Dividend Yield | ★ 2.46% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.73 | N/A |
| Revenue | ★ $1,311,845,000.00 | $3,510,000.00 |
| Revenue This Year | N/A | $3,246.44 |
| Revenue Next Year | $9.26 | $135.19 |
| P/E Ratio | $15.49 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.09 | $30.04 |
| 52 Week High | $27.47 | $78.48 |
| Indicator | MGY | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 60.54 | 50.03 |
| Support Level | $25.53 | $46.48 |
| Resistance Level | $27.47 | $50.63 |
| Average True Range (ATR) | 0.80 | 2.65 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 57.10 | 58.89 |
Magnolia Oil & Gas Corp is an independent oil and natural gas company engaged in the acquisition, development, exploration, and production of oil, natural gas, and natural gas liquid (NGL) reserves. The company's oil and natural gas properties are located in Karnes County and the Giddings area in South Texas, where the Company targets the Eagle Ford Shale and Austin Chalk formations. Its objective is to generate stock market value over the long term through consistent organic production growth, high full-cycle operating margins, and an efficient capital program with short economic paybacks. The company's operating segment is acquisition, development, exploration, and production of oil and natural gas properties located in the United States.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.